{"analyses":[{"ciLowerLimit":"0.27","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.95","estimateComment":"Reference arm = Chemotherapy","groupDescription":"Sample size of 89 provided 80% power to detect a hazard ratio of 0.63 at a one-sided alpha level of 0.15.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.015","pValueComment":"One-sided significance level = 0.15","paramType":"Hazard Ratio (HR)","paramValue":"0.51","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"There were not enough events to estimate the upper confidence boundary.","groupId":"OG000","lowerLimit":"1.0","upperLimit":"NA","value":"2.1"},{"comment":"The median has not yet been reached. Additionally there were not enough events to estimate the upper confidence boundary.","groupId":"OG001","lowerLimit":"3.3","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"Progression is defined as any of the following: more than 25% increase in the contrast-enhancing lesion seen on magnetic resonance imaging (MRI) compared with baseline or best response; new site of disease (central nervous system or systemic); recurrent or new ocular disease; recurrent or positive cerebrospinal fluid (CSF) cytology. Progression-free survival time is defined as time from randomization to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 3-5 weeks later by two 28-day cycles of cytarabine.","id":"OG000","title":"Chemotherapy"},{"description":"Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 2-5 weeks later by 3 weeks of low-dose whole-brain radiotherapy (WBRT), followed 3-5 weeks later by two 28-day cycles of cytarabine.","id":"OG001","title":"Chemotherapy + Low-Dose WBRT"}],"paramType":"MEDIAN","populationDescription":"Eligible participants","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 7.3 years.","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"years"}